# US 11,896,632 B2 · Methods for inhibiting growth of oral pathogenic bacteria and alleviating oral pathogenic bacteria-associated disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,632 B2
- Document ID: US11896632B2
- Status: Granted
- Kind: B2
- Application number: 17/573,049
- Filed: 2022-01-11
- Published: 2023-02-02
- Granted: 2024-02-13
- Earliest claimed: 2021-07-26
- Assignees: Glac Biotech Co., Ltd.
- Applicants: Glac Biotech Co., Ltd.
- Inventors: Hsieh-Hsun Ho; Yi-Wei Kuo; Ching-Wei Chen; Wen-Yang Lin; Jui-Fen Chen; Shu-Hui Chen
- Web page: https://patentgrep.com/patent/US11896632B2

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 8/99: from microorganisms other than algae or fungi, e.g. protozoa or bacteria
- A61P 31/04: Antibacterial agents
- A61Q 17/005: {Antimicrobial preparations}
- C12N 1/205: Bacterial isolates
- A61Q 11/00: Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
- C12R 2001/225: Lactobacillus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Disclosed herein are methods for inhibiting growth of oral pathogenic bacteria and alleviating an oral pathogenic bacteria-associated disorder using a culture of at least one lactic acid bacterial strain selected from the group consisting of Lactobacillus rhamnosus MP108 which is deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 21225, and Lactobacillus paracasei MP137 which is deposited at the CGMCC under an accession number CGMCC 21224.

## Claims

### Claim 1

A method for inhibiting growth of oral pathogenic bacteria, comprising applying a composition including liquid cultures of Lactobacillus rhamnosus MP108 and Lactobacillus paracasei MP137, which are deposited at the China General Microbiological Culture Collection Center (CGMCC) under accession numbers CGMCC 21225 and CGMCC 21224, respectively,
wherein the liquid cultures are substantially free of bacterial cells, and a volume ratio of the liquid cultures of Lactobacillus rhamnosus MP108 and Lactobacillus paracasei MP137 in the composition ranges from 1:0.43 to 1:2.33.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the liquid cultures are heat-inactivated.

### Claim 3 (depends on 1)

The method as claimed in claim 1, wherein the oral pathogenic bacteria are selected from the group consisting of Streptococcus mutans, Porphyromonas gingivalis, Fusobacterium nucleatum subsp. polymorphum, Aggregatibacter actinomycetemcomitans, Treponema denticola, Prevotella intermedia, Parvimonas micra, Campylobacter rectus, Eikenella corrodens, and combinations thereof.

### Claim 4 (depends on 1)

The method as claimed in claim 1, wherein the composition is formulated as a food product, a pharmaceutical composition or an oral hygiene composition.

### Claim 5

A method for alleviating an oral pathogenic bacteria-associated disorder, comprising administering to a subject in need thereof a composition including liquid cultures of Lactobacillus rhamnosus MP108 and Lactobacillus paracasei MP137, which are deposited at the China General Microbiological Culture Collection Center (CGMCC) under accession numbers CGMCC 21225 and CGMCC 21224, respectively,
wherein the liquid cultures are substantially free of bacterial cells, and a volume ratio of the liquid cultures of Lactobacillus rhamnosus MP108 and Lactobacillus paracasei MP137 in the composition ranges from 1:0.43 to 1:2.33.

### Claim 6 (depends on 5)

The method as claimed in claim 5, wherein the liquid cultures are heat-inactivated.

### Claim 7 (depends on 5)

The method as claimed in claim 5, wherein the oral pathogenic bacteria are selected from the group consisting of Streptococcus mutans, Porphyromonas gingivalis, Fusobacterium nucleatum subsp. polymorphum, Aggregatibacter actinomycetemcomitans, Treponema denticola, Prevotella intermedia, Parvimonas micra, Campylobacter rectus, Eikenella corrodens, and combinations thereof.

### Claim 8 (depends on 5)

The method as claimed in claim 5, wherein the composition is formulated as a food product, a pharmaceutical composition or an oral hygiene composition.